South African drugmaker Aspen terminates talks with potential European partner


JOHANNESBURG (Reuters) – South African drugmaker Aspen Pharmacare said on Friday it had terminated talks with a potential partner in Europe, after announcing in March a strategic review of its European and domestic commercial pharmaceuticals businesses.

“Shareholders are advised that Aspen is now in a position to explore options with other potential partners in order to optimise its European Commercial Pharmaceuticals business,” Aspen said in a statement.

Without giving details, in March, Aspen said under the first phase of the review it would split its South African commercial pharmaceuticals business into two divisions to sharpen its focus.

Over the past five years Aspen has transitioned from a generics-focused pharmaceutical business operating in a few select countries into a multi-national firm with strong regional brands and diversifying into specialised therapies such as thrombosis and anaesthetics.

Reporting by Olivia Kumwenda-Mtambo; editing by David Evans

Previous articleRand rattled by stronger U.S payrolls data, South African stocks slip
Next articleNigeria’s Buhari to sign AfTFCA in AU Summit
Godwin Okafor is a Financial Journalist, Internet Social Entrepreneur and Founder of Naija247news Media Limited. He has over 16 years experience in financial journalism. His experience cuts across traditional and digital media. He started his journalism career at Business Day, Nigeria and founded Naija247news Media in 2010. Godwin holds a Bachelors degree in Industrial Relations and Personnel Management from the Lagos State University, Ojo, Lagos. He is an alumni of Lagos Business School and a Fellow of the University of Pennsylvania (Wharton Seminar for Business Journalists). Over the years, he has won a number of journalism awards. Godwin is the chairman of Emmerich Resources Limited, the publisher of Naija247news.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.